MediWales Innovation Award
AlgiPharma has been recognized for its innovative alginate oligomer technology being developed for the treatment of respiratory diseases, and biofilm infections. The award was sponsored and presented by Dr. Richard Thompson from the Development Bank of Wales. Leaders from industry, the NHS, government and academia gathered for the MediWales Innovation Awards, celebrating the year’s biggest achievements in the Welsh life sciences sector. Pictured (Left to right): Robert Thompson from the Development Bank of Wales who presented the award; Prof David Thomas, University of Cardiff; Dr. Philip D. Rye, R&D Director at AlgiPharma.
The black tie event was held on 4th December at Cardiff’s National Museum of Wales and delivered with support from BioWales, the Welsh Government’s Healthcare Technology, Strategy & Innovation Team and Health & Care Research Wales.
MediWales is the life science network for Wales, with over 200 members including pharmaceutical and health tech companies, NHS health boards, university departments, and professional services and suppliers. MediWales provides advice, support and business opportunities for its members, while promoting collaboration within the life science community in Wales. Every year, MediWales produces a range of publications and organises events including the all Wales NHS conference MediWales Connects, the UK HealthTech conference and the MediWales Innovation Awards.
About AlgiPharma AS:
AlgiPharma AS is a clinical stage pharmaceutical company with headquarters in Norway. It was founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis.
AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.
AlgiPharma has received more than USD 37 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, US Army through Congressional Earmark funding, and the Cystic Fibrosis Foundation (CFF). Please see latest award from CFF.
AlgiPharma is a privately owned company registered and domiciled in Norway.
For additional information contact:
Yngvar P. Berg, CEO: email@example.com
Arne Dessen, COO and Chairman of the Board: firstname.lastname@example.org